Quantcast

Latest Anastrozole Stories

2010-10-20 08:20:09

(Ivanhoe Newswire) "“ Big joy for soy!  New research finds that high amounts of the wholesome combination of protein, isoflavones and fiber that make up soy lower the risk of cancer recurrence in post-menopausal breast cancer patients with hormone-sensitive cancers.  Soy has already been investigated for benefit in terms of cardiovascular disease, weight loss, arthritis, brain function, as well as exercise performance enhancement. Soy isoflavones are comparable to estrogen in...

2010-09-09 09:17:00

ANN ARBOR, Mich., Sept. 9 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of...

2010-07-08 15:47:00

COLUMBUS, Ohio, July 8 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1mg by the U.S. Food and Drug Administration. The product is available in bottles of 30 for immediate shipment to wholesalers and pharmacies nationwide. Roxane Laboratories' Anastrozole Tablets are AB rated to ARIMIDEX® (anastrozole) tablets. Annual sales of ARIMIDEX® are approximately...

2010-07-01 06:00:00

WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced a new patient support program for postmenopausal women with hormone receptor-positive early breast cancer who are prescribed ARIMIDEX. The program is designed to provide eligible patients with instant discounts, potentially saving the patient up to $300. (Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) When using the...

2010-06-29 06:30:00

PITTSBURGH, June 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer. Anastrozole Tablets had U.S. sales of approximately $917 million for the 12 months ending...

2010-06-28 18:15:00

BOCA RATON, Fla., June 28 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that they will launch Anastrozole 1mg Tablets. The U.S. Food and Drug Administration has granted final approval for the Abbreviated New Drug Application (ANDA) for this first time generic, which is being supplied under a licensing agreement. Anastrozole Tablets are AB rated to Arimidex®, a billion dollar cancer drug marketed by AstraZeneca. Breckenridge will launch the product...

b67bd9b7dcb2202fe5feef6e85df9c27
2010-03-10 12:01:40

Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy. Fulvestrant appeared to exert maximum anti-cancer effects in vitro when cells produced normal or elevated quantities of the cytokeratins CK8 and CK18, structural proteins that help give the nucleus its shape. For fulvestrant to work well, the cells must...

2010-03-08 15:34:00

REDWOOD CITY, Calif., March 8 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of positive results from a large international study which demonstrated that the Oncotype DX® breast cancer Recurrence Score® (RS) result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive, postmenopausal breast cancer patients who are treated with either...

2009-12-10 16:00:00

WILMINGTON, Del., Dec. 10 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20% (HR 0.80; 95% CI 0.68-0.94, p=0.006) when compared with fulvestrant 250 mg, the dose...

2009-12-02 13:05:17

Even when informed about risks, benefits, only 6% would take drug Even when women at high-risk of breast cancer are well-informed about the risks and benefits of using the drug tamoxifen for prevention, only 6 percent said they were likely to take it. Researchers at the University of Michigan Comprehensive Cancer Center created a decision aid designed to inform women about the risks and benefits associated with tamoxifen, a drug that was first used to stop breast cancer from returning and has...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related